Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity
Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity
复制标题
白细胞介素-1 (IL-1) 受体拮抗剂和可溶性 IL-1 受体抑制慢性粒细胞白血病集落生长:IL-1 活性抑制剂的新应用
DOI:
10.1182/blood.v78.6.1476.bloodjournal7861476
复制
发表时间:
1991
期刊:
影响因子:
20.3
通讯作者:
M. Talpaz
中科院分区:
文献类型:
--
作者:
Z. Estrov;R. Kurzrock;M. Wetzler;H. Kantarjian;M. Blake;D. Harris;J. Gutterman;M. Talpaz
In this study, we investigated the role of interleukin-1 beta (IL-1 beta) in the malignant evolution of chronic myelogenous leukemia (CML) and the functional activity of IL-1 inhibitors. Bone marrow (BM) and peripheral blood (PB) low-density cells from 38 CML patients were studied in the colony-forming unit-granulocyte, erythrocyte, monocyte, megakaryocyte colony culture assay. Samples from patients with early stage, interferon-alpha (IFN)-sensitive disease formed hematopoietic colonies in the presence of fetal calf serum (FCS), erythropoietin (Epo), and one of the following: granulocyte-macrophage colony- stimulating factor (10 ng/mL), IL-3 (15 ng/mL), both, or phytohemagglutinin-conditioned medium. The addition of IL-1 beta augmented IFN-sensitive CML colony growth in a dose-dependent manner at concentrations of 10 to 100 U/mL. In sharp contrast, addition of the above growth factors did not augment the colony growth-promoting effect of FCS and Epo in samples from IFN-resistant patients; further, adherent cell fractionation or T-lymphocyte depletion attenuated the “autonomous” colony growth. Lysates of 2.5 x 10(7) low-density cells from each of six IFN-resistant and six IFN-sensitive CML patients and three normal volunteers were tested for intrinsic IL-1 beta content in an enzyme-linked immunosorbent assay and yielded a mean of 610 pg, 54.6 pg, and 49.4 pg of IL-1 beta, respectively (P less than .045). Interestingly, both soluble IL-1 receptors (sIL-1R) and IL-1 receptor antagonist (IL-1RA) at concentrations of 5 to 100 ng/mL (sIL-1R) and 10 to 500 ng/mL (IL-1RA) inhibited CML colony growth in a dose-dependent fashion, with maximal inhibition of 64% and 65%, respectively. A similar effect was noted with the use of anti-IL-1 beta neutralizing antibodies. These data implicate IL-1 beta in CML disease progression and suggest that the inhibitory effects of molecules such as sIL-1R and IL-1RA could conceivably be the basis of a novel therapeutic strategy against this disorder.
登录
查看更多内容
影响因子:
4.4
作者:
C. Dinarello;T. Ikejima;S. Warner;S. Orencole;G. Lonnemann;Joseph G. Cannon;P. Libby
通讯作者:
C. Dinarello;T. Ikejima;S. Warner;S. Orencole;G. Lonnemann;Joseph G. Cannon;P. Libby
影响因子:
20.3
作者:
Richard E. Champlin;David W. Golde
通讯作者:
Richard E. Champlin;David W. Golde
DOI:
10.1073/pnas.81.24.7907
发表时间:
1984-01-01
期刊:
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES
影响因子:
--
作者:
AURON, PE;WEBB, AC;DINARELLO, CA
通讯作者:
DINARELLO, CA
影响因子:
--
作者:
DINARELLO, CA
通讯作者:
DINARELLO, CA
影响因子:
20.3
作者:
Kantarjian,HM;Smith,TL;McCredie,KB;Keating,MJ;Walters,RS;Talpaz,M;Hester,JP;Bligham,G;Gehan,E;Freireich,EJ
通讯作者:
Freireich,EJ